Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, specializing in the discovery and development of antibody-based therapeutics, primarily for oncology and hematology. The company applies proprietary technology platforms—including DuoBody, HexaBody, DuoHexaBody and related antibody engineering approaches—to create next‑generation monoclonal and bispecific antibodies.
Genmab advances its pipeline through a mix of in‑house development and global partnerships, generating revenue from product sales (in partnered markets), royalties, and milestone payments. Notable programs originating from Genmab’s science include daratumumab (marketed by Janssen Biotech, a Johnson & Johnson company), epcoritamab (co-developed and co-commercialized with AbbVie), and tisotumab vedotin (co-developed with Seagen). The company operates internationally with R&D and commercial activities across Europe and the United States, and its shares are listed on Nasdaq Copenhagen and on Nasdaq in the United States under the ticker GMAB.
To provide comprehensive coverage, we aggregate data and news under the name Genmab, encompassing the following company names, divisions, and related entities:
Genmab Holding II B.V. and Genmab Finance LLC.
This list encompasses current and former names, alternate names, and key divisions associated with Genmab, ensuring you can easily find all relevant information under a single, unified profile.
